| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 904.2 | 1064.7 | 949.5 |
| Other income | 12.0 | 18.3 | 14.5 |
| Total income | 916.2 | 1083.0 | 964.0 |
| Profit before exceptional items & tax | 161.9 | 266.9 | 193.0 |
| Exceptional items | -27.2 | 0.0 | 0.0 |
| Profit before tax | 134.7 | 266.9 | 193.0 |
| Net profit | 101.4 | 197.9 | 145.7 |
| Operating margin | 14.7% | 24.6% | 20.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -30.40% |
|---|---|
| Net profit, quarter on quarter | -48.80% |
| Revenue, year on year | -4.80% |
BSE results filing, NSE: JBCHEPHARM. Figures extracted from the filing.
More from JB Chemicals & Pharmaceuticals Ltd
All →J B Chemicals & Pharmaceuticals Earnings Call: Key Takeaways
Q4 FY26 marked an operational reset following Torrent Pharma's acquisition of a controlling stake. Management focused on integration, distribution optimization, and rationalizing low-margin trade generics.
J B Chemicals & Pharmaceuticals Earnings Call: Key Takeaways
Q4 FY26 shows operational reset post Torrent Pharma acquisition; revenue at ₹904cr (down 5% YoY) with adjusted EBITDA margin improving to 27%.
J B Chemicals & Pharmaceuticals Earnings Call: Key Takeaways
This was an operational reset quarter following Torrent Pharma's acquisition, marked by intentional portfolio pruning and alignment of trade practices with the new parent entity.
J B Chemicals & Pharmaceuticals Earnings Call: Key Takeaways
JB Pharma underwent an operational reset in Q4 FY26 following the Torrent Pharma acquisition. Revenue dipped 5% to ₹904cr due to the discontinuation of low-margin trade generics and distribution realignment.